Cargando…

The medical treatment with pasireotide in Cushing’s disease: an Italian multicentre experience based on “real-world evidence”

A phase III study has demonstrated that 6-month pasireotide treatment induced disease control with good safety in 15–26% of patients with Cushing’s disease (CD). The aim of the current study was to evaluate the 6-month efficacy and safety of pasireotide treatment according to the real-world evidence...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pivonello, Rosario, Arnaldi, Giorgio, Scaroni, Carla, Giordano, Carla, Cannavò, Salvo, Iacuaniello, Davide, Trementino, Laura, Zilio, Marialuisa, Guarnotta, Valentina, Albani, Adriana, Cozzolino, Alessia, Michetti, Grazia, Boscaro, Marco, Colao, Annamaria
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2019
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6551343/ https://www.ncbi.nlm.nih.gov/pubmed/30968338 http://dx.doi.org/10.1007/s12020-018-1818-7

Ejemplares similares

Approach to patients with pseudo-Cushing’s states
por: Scaroni, Carla, et al.
Publicado: (2019)

Clinical use of pasireotide for Cushing’s disease in adults
por: Ceccato, Filippo, et al.
Publicado: (2015)

Incretin Response to Mixed Meal Challenge in Active Cushing’s Disease and after Pasireotide Therapy
por: Barbot, Mattia, et al.
Publicado: (2022)

The treatment with pasireotide in Cushing’s disease: effect of long-term treatment on clinical picture and metabolic profile and management of adverse events in the experience of a single center
por: Simeoli, C., et al.
Publicado: (2019)

Neuropsychiatric disorders in Cushing's syndrome
por: Pivonello, Rosario, et al.
Publicado: (2015)

Managing hyperglycemia in patients with Cushing’s disease treated with pasireotide: medical expert recommendations
por: Colao, Annamaria, et al.
Publicado: (2013)

Glucocorticoid excess and COVID-19 disease
por: Guarnotta, Valentina, et al.
Publicado: (2020)

Cushing’s disease: adrenal steroidogenesis inhibitors
por: Pivonello, Rosario, et al.
Publicado: (2022)

A New Clinical Model to Estimate the Pre-Test Probability of Cushing’s Syndrome: The Cushing Score
por: Parasiliti-Caprino, Mirko, et al.
Publicado: (2021)

Long-term treatment of Cushing’s disease with pasireotide: 5-year results from an open-label extension study of a Phase III trial
por: Petersenn, S., et al.
Publicado: (2017)

Long-term efficacy and safety of subcutaneous pasireotide alone or in combination with cabergoline in Cushing’s disease
por: Feelders, Richard A., et al.
Publicado: (2023)

Pasireotide can induce sustained decreases in urinary cortisol and provide clinical benefit in patients with Cushing’s disease: results from an open-ended, open-label extension trial
por: Schopohl, Jochen, et al.
Publicado: (2014)

The hypertension of Cushing's syndrome: controversies in the pathophysiology and focus on cardiovascular complications
por: Isidori, Andrea M., et al.
Publicado: (2015)

Hyperglycemia induced by pasireotide in patients with Cushing’s disease or acromegaly
por: Silverstein, Julie M.
Publicado: (2016)

Vitamin D Deficiency in Cushing’s Disease: Before and After Its Supplementation
por: Guarnotta, Valentina, et al.
Publicado: (2022)

New treatment guidelines on Cushing's disease
por: Arnaldi, Giorgio, et al.
Publicado: (2009)

The dopaminergic control of Cushing’s syndrome
por: Pivonello, R., et al.
Publicado: (2022)

Extended treatment of Cushing’s disease with pasireotide: results from a 2-year, Phase II study
por: Boscaro, M., et al.
Publicado: (2013)

Pasireotide treatment significantly reduces tumor volume in patients with Cushing’s disease: results from a Phase 3 study
por: Lacroix, André, et al.
Publicado: (2019)

Prolactinomas, Cushing's disease and acromegaly: debating the role of medical therapy for secretory pituitary adenomas
por: Biller, Beverly MK, et al.
Publicado: (2010)

MON-445 Long-Term Results of an Ongoing Non-Interventional, Real-World Observational Study of Pasireotide SC in Cushing's Disease
por: Yuen, Kevin, et al.
Publicado: (2019)

Efficacy of combined treatment with pasireotide, pegvisomant and cabergoline in an acromegalic patient resistant to other treatments: a case report
por: Ciresi, A., et al.
Publicado: (2018)

Circulating Irisin Levels as a Marker of Osteosarcopenic-Obesity in Cushing’s Disease
por: Guarnotta, Valentina, et al.
Publicado: (2020)

SUN-463 Tumor Shrinkage with Preoperative Relacorilant Therapy in Two Patients with Cushing Disease Due to Pituitary Macroadenomas
por: Terzolo, Massimo, et al.
Publicado: (2019)

Nutritional Intervention in Cushing’s Disease: The Ketogenic Diet’s Effects on Metabolic Comorbidities and Adrenal Steroids
por: Guarnotta, Valentina, et al.
Publicado: (2023)

Diabetes Mellitus Secondary to Cushing’s Disease
por: Barbot, Mattia, et al.
Publicado: (2018)

Monitoring Patient Improvement Parameters following Pasireotide Treatment in Cushing's Disease
por: Yedinak, Chris, et al.
Publicado: (2013)

Resolution of Cyclicity After Pasireotide LAR in a Patient With Cushing Disease
por: Machado, Márcio Carlos, et al.
Publicado: (2021)

Pasireotide treatment in Cushing’s disease: A single tertiary center’s experience
por: ŞAHİN, Serdar, et al.
Publicado: (2021)

Effectiveness of low-dose pasireotide in a patient with Cushing’s disease: antiproliferative effect and predictivity of a short pasireotide suppression test
por: Grossrubatscher, Erika, et al.
Publicado: (2015)

The Pathophysiology and Treatment of Hypertension in Patients With Cushing's Syndrome
por: Barbot, Mattia, et al.
Publicado: (2019)

Pasireotide-resistant Refractory Cushing's Disease without Somatostatin Receptor 5 Expression
por: Mizuno, Tomoko, et al.
Publicado: (2021)

Late-night salivary cortisol may be valuable for assessing treatment response in patients with Cushing’s disease: 12-month, Phase III pasireotide study
por: Findling, James W., et al.
Publicado: (2016)

Medical Treatment of Cushing's Disease: An Overview of the Current and Recent Clinical Trials
por: Pivonello, Rosario, et al.
Publicado: (2020)

Long-term safety and efficacy of subcutaneous pasireotide in patients with Cushing’s disease: interim results from a long-term real-world evidence study
por: Manetti, Luca, et al.
Publicado: (2019)

COVID-19 and Cushing's syndrome: recommendations for a special population with endogenous glucocorticoid excess
por: Pivonello, Rosario, et al.
Publicado: (2020)

Pasireotide-Induced Shrinkage in GH and ACTH Secreting Pituitary Adenoma: A Systematic Review and Meta-Analysis
por: Mondin, Alessandro, et al.
Publicado: (2022)

Consideration on TMPRSS2 and the risk of COVID-19 infection in Cushing’s syndrome
por: Barbot, Mattia, et al.
Publicado: (2020)

Efficacy and safety of pasireotide for Cushing's disease: A protocol for systematic review and meta-analysis
por: Zhao, Nairui, et al.
Publicado: (2020)

Unmet needs on the current medical management of Cushing’s syndrome: results from a Delphi panel of Italian endocrinologists
por: Pivonello, R., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_neq1k2be2o8bgggovqhhi59fi1